Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologyCommunity-Care mepolizumab Coverage Prior Auth | O…
    Ask Trek AI about this page
    CurrentCommunity-CarePolicy N/A

    Mepolizumab (medical benefit) utilization — coverage criteria

    Customize your policy alerts

    Sign up for all Community-Care policy alerts

    Know when Community-Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy defines medical necessity criteria, quantity limits, authorization periods, and prescribing requirements for mepolizumab across multiple eosinophil-related indications for Community-Care members.

    Policy Summary
    PayerCommunity-Care
    PolicyMepolizumab (medical benefit) utilization — coverage criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewDec 1, 2025
    Next Review DateDec 1, 2025
    Key ActionObtain prior authorization with indication-specific criteria met and required documentation including specialist involvement, eosinophil count, exacerbation history, and prior therapy trials.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5indications covered
    100 mgusual dose (asthma/CRSwNP/COPD)
    300 mgdose (EGPA/HES)

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 moinitial auth period
    oftenspecialist required

    Coverage and Medical Necessity Criteria

    Initial Approval — Asthma

    Covered when ALL of the following are met

    Asthma initial criteria: Patient is >= 6 years of age; prescribed by, or in consultation with, an allergist, pulmonologist, or immunologist; diagnosis of severe asthma; diagnosis of eosinophilic asthma with a provided baseline blood eosinophil concentration >= 150 cells/µL; history of >= 2 asthma exacerbations requiring systemic corticosteroids or emergency department visit or hospitalization for treatment of asthma within the past year despite adherent utilization of either an inhaled corticosteroid (ICS) with 1 additional asthma controller medication or maximally tolerated inhaled corticosteroid/long-acting beta agonist (ICS/LABA) combination product; prescriber attests that the patient is adherent to controller medications and that mepolizumab will not be used in combination with another targeted immunomodulator product used for asthma.age >=6; eos >=150; >=2 exacerbations

    Prescriber attestation required regarding adherence and non-concomitant targeted immunomodulator use

    Initial Approval — Chronic rhinosinusitis with nasal polyps (CRSwNP)

    Covered when ALL of the following are met

    CRSwNP initial criteria: Patient is >= 18 years of age; prescribed by, or in consultation with, an allergist, immunologist, or otolaryngologist; diagnosis of chronic rhinosinusitis with nasal polyposis lasting at least 12 weeks; bilateral nasal polyposis confirmed with nasal endoscopy or sinus CT scan; trial of a nasal corticosteroid spray was ineffective, contraindicated, or not tolerated; moderate to severe symptoms of nasal congestion, blockage, or obstruction (such as loss of smell, rhinorrhea, or facial pain).age >=18; duration >=12 weeks

    Nasal endoscopy or sinus CT confirmation required

    Initial Approval — Eosinophilic granulomatosis with polyangiitis (EGPA)

    Covered when ALL of the following are met

    EGPA initial criteria: Patient is >= 18 years of age; prescribed by, or in consultation with, a rheumatologist, allergist, pulmonologist, or immunologist; diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA); one of the following baseline blood eosinophil criteria: > 1000 cells/µL OR > 10% of the total leukocyte count; trial of oral corticosteroid therapy equivalent to prednisone 7.5 mg/day for a minimum of 4 weeks was ineffective, contraindicated, or not tolerated.age >=18; eos >1000 or >10%

    Specialist involvement and corticosteroid trial required

    Initial Approval — Hypereosinophilic Syndrome (HES)

    Covered when ALL of the following are met

    HES initial criteria: Prescribed by, or in consultation with, a rheumatologist, allergist, pulmonologist, gastroenterologist, hematologist, or other specialist experienced in HES; patient is >= 12 years of age; diagnosis of hypereosinophilic syndrome (HES) without clinical features consistent with a myeloid disorder; HES has persisted for at least 6 months; blood eosinophils > 1000 cells/µL; >= 2 HES flares within the past 12 months; trial of corticosteroids and/or second-line steroid-sparing agent (eg hydroxyurea or interferon alfa) was ineffective, not tolerated, or contraindicated.age >=12; eos >1000; >=2 flares in 12 months; duration >=6 months

    Specialist involvement and prior therapy required

    Initial Approval — Chronic Obstructive Pulmonary Disease (COPD)

    Covered when ALL of the following are met

    COPD initial criteria: Prescribed by, or in consultation with, an allergist, pulmonologist, or immunologist; diagnosis of chronic obstructive pulmonary disease (COPD) with eosinophilic phenotype and a provided baseline blood eosinophil concentration >= 300 cells/µL; history of >= 2 moderate COPD exacerbations or >= 1 severe COPD exacerbation within the past year despite adherent utilization of maintenance triple therapy (LAMA/LABA/ICS); will not be used in combination with another targeted immunomodulator product used for COPD or asthma.eos >=300; >=2 moderate or >=1 severe exacerbation

    Specialist involvement and adherence to triple therapy required

    Continuation of Therapy

    Covered when ALL of the following are met (per-indication)

    Asthma continuation: Diagnosis of eosinophilic asthma; positive clinical response has been achieved; will not be used in combination with another targeted immunomodulator product used for asthma.positive clinical response

    Continuation requires documented benefit

    CRSwNP continuation: Diagnosis of chronic rhinosinusitis with nasal polyposis; positive clinical response has been achieved.positive clinical response

    Continuation requires documented benefit

    EGPA continuation: Diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA); positive clinical response has been achieved.positive clinical response

    Use of mepolizumab in combination with another targeted immunomodulator for asthma or COPD is not permitted. Prescribers must attest that mepolizumab will not be administered concomitantly with any other targeted immunomodulator product for these indications; continuation criteria also require absence of combination use. Failure to confirm non‑concomitant use may result in denial of coverage.

    Coverage requires appropriate specialist involvement and documentation specific to each indication. For asthma and COPD, prescriptions must be written by or in consultation with an allergist, pulmonologist, or immunologist. EGPA and HES require specialist prescribing or consultation (EGPA: rheumatologist, allergist, pulmonologist, or immunologist; HES: a specialist experienced in HES such as rheumatologist, allergist, pulmonologist, gastroenterologist, or hematologist).

    Eosinophil thresholds and exacerbation history are required where specified: for eosinophilic asthma a baseline blood eosinophil concentration of ≥ 150 cells/µL; for COPD an eosinophil concentration of ≥ 300 cells/µL; for EGPA and HES blood eosinophils must exceed intense thresholds (EGPA: > 1000 cells/µL or >10% of total leukocytes; HES: > 1000 cells/µL).

    Prior therapy trials are also required per indication and must be documented: asthma requires prior use of an inhaled corticosteroid plus an additional controller or maximally tolerated ICS/LABA; CRSwNP requires trial of a nasal corticosteroid spray; EGPA requires a trial of oral corticosteroid therapy equivalent to prednisone 7.5 mg/day for ≥4 weeks; HES requires trial of corticosteroids and/or second‑line steroid‑sparing agents; COPD requires adherent use of maintenance triple therapy (LAMA/LABA/ICS). Where continuation is requested, documentation of a positive clinical response is required.

    Billing and Laboratory Thresholds

    Applicable HCPCS CodeHCPCS
    J2182Injection, mepolizumab, 1 mg
    Asthma eosinophil threshold
    Asthma eosinophil threshold>= 150 cells/µL
    Applies toInitial approval for eosinophilic asthma (age >= 6 years)
    Documented asBaseline blood eosinophil concentration must be provided
    COPD eosinophil threshold
    COPD eosinophil threshold>= 300 cells/µL
    Applies toInitial approval for eosinophilic COPD phenotype
    Prescriber requirementPrescribed by or in consultation with an allergist, pulmonologist, or immunologist

    Prior Authorization, Documentation, and Denial Triggers

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for mepolizumab (HCPCS code J2182). Requests must include a clear indication and supporting documentation as outlined below. Submit prior authorization requests per payer procedures before drug administration or billing.

    • HCPCS: J2182 (Injection, mepolizumab, 1 mg)
    Step Therapy

    Required Prior Therapy Trials

    Prior therapy trials are required for initial approval and must be documented in the prior authorization request. For asthma: trial and continued use of an inhaled corticosteroid (ICS) plus at least one additional controller medication, or maximally tolerated ICS/LABA combination therapy, with persistent exacerbations despite adherence. For chronic rhinosinusitis with nasal polyps: trial of a nasal corticosteroid spray that was ineffective, contraindicated, or not tolerated. For EGPA and HES: trial of systemic corticosteroid therapy (EGPA: prednisone ≈7.5 mg/day for ≥4 weeks) or other steroid-sparing agents for HES unless contraindicated or not tolerated. For COPD: adherence to maintenance triple therapy (LAMA/LABA/ICS) with persistent exacerbations.

    Background

    Mepolizumab is an anti‑eosinophil targeted immunomodulator indicated across multiple eosinophil‑driven conditions. The policy covers its use for eosinophilic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), and eosinophilic phenotypes of COPD when indication‑specific criteria — including specialist involvement, required eosinophil thresholds, prior therapy trials, and demonstration of clinical benefit for continuation — are met.

    Key Definitions

    EGPA — definition
    TermEosinophilic granulomatosis with polyangiitis (EGPA)
    Also known asChurg-Strauss Syndrome
    Prescriber requirementPrescribed by or in consultation with a rheumatologist, allergist, pulmonologist, or immunologist
    HES — definition
    TermHypereosinophilic syndrome (HES)
    Diagnostic notesHES without clinical features consistent with a myeloid disorder and persistent for at least six months
    Additional criteriaBlood eosinophils > 1000 cells/µL and >=2 HES flares in past 12 months; specialist involvement required
    Policy Summary
    PayerCommunity-Care
    PolicyMepolizumab (medical benefit) utilization — coverage criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewDec 1, 2025
    Next Review DateDec 1, 2025
    Key ActionObtain prior authorization with indication-specific criteria met and required documentation including specialist involvement, eosinophil count, exacerbation history, and prior therapy trials.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaBilling and Laboratory ThresholdsPrior Authorization, Documentation, and Denial TriggersBackgroundKey Definitions

    Continuation requires documented benefit

    HES continuation: Diagnosis of hypereosinophilic syndrome (HES) without clinical features consistent with a myeloid disorder; positive clinical response has been achieved.positive clinical response

    Continuation requires documented benefit

    COPD continuation: Diagnosis of chronic obstructive pulmonary disease (COPD); positive clinical response with use of mepolizumab has been achieved; will not be used in combination with another targeted immunomodulator product used for COPD or asthma.positive clinical response

    Continuation requires documented benefit

    EGPA eosinophil criteria
    EGPA eosinophil criteria> 1000 cells/µL OR > 10% of total leukocyte count
    Applies toInitial approval for eosinophilic granulomatosis with polyangiitis (EGPA)
    Additional requirementTrial of oral corticosteroid therapy (prednisone 7.5 mg/day equivalent for >=4 weeks) required unless ineffective, contraindicated, or not tolerated
    HES eosinophil threshold
    HES eosinophil threshold> 1000 cells/µL
    Applies toInitial approval for hypereosinophilic syndrome (HES)
    Additional requirementsHES persistent >= 6 months and >=2 HES flares in past 12 months; specialist involvement required
  1. Asthma: documentation of adherence to ICS + 1 additional controller or maximally tolerated ICS/LABA and ≥2 exacerbations in past year despite therapy
  2. CRSwNP: trial of nasal corticosteroid spray ineffective, contraindicated, or not tolerated
  3. EGPA: trial of oral corticosteroid therapy (prednisone ≈7.5 mg/day for ≥4 weeks) ineffective, contraindicated, or not tolerated
  4. HES: trial of corticosteroids and/or steroid-sparing agent ineffective, contraindicated, or not tolerated
  5. COPD: adherence to maintenance triple therapy (LAMA/LABA/ICS) with ≥2 moderate or ≥1 severe exacerbation in past year
  6. Documentation Required

    Required Documentation

    Prescriber specialty and baseline clinical data must be provided with the authorization request. Required documentation includes age, specialty prescriber or documented consultation, confirmed diagnosis, and baseline blood eosinophil concentration where applicable. Also include prior exacerbation history, trials of prior therapies, and attestation that mepolizumab will not be used concurrently with another targeted immunomodulator for the same condition.

    • Age of patient
    • Specialist prescriber or documented consultation (allergist, pulmonologist, immunologist, rheumatologist, otolaryngologist, hematologist, or other appropriate specialist as indicated)
    • Confirmed diagnosis relevant to the requested indication (e.g., eosinophilic asthma, CRSwNP, EGPA, HES, COPD)
    • Baseline blood eosinophil concentration (e.g., ≥150 cells/µL for asthma; ≥300 cells/µL for COPD; thresholds per indication)
    • History of exacerbations and prior medication trials (see prior therapy trials)
    • Prescriber attestation of adherence to controller medications and that therapy will not be combined with another targeted immunomodulator
    Denial Risk

    Denial Triggers

    Authorization may be denied if required criteria or documentation are not met. Common reasons for denial include lack of specialist involvement or documented consultation, failure to meet eosinophil or exacerbation thresholds, inadequate or undocumented trials of prior therapies, use in combination with another targeted immunomodulator, or missing baseline laboratory data.

    • No specialist prescriber or no documented consultation when required
    • Baseline blood eosinophil concentration below indication-specific threshold or not provided
    • Insufficient history of exacerbations or failure to document prior controller therapy trials
    • Use in combination with another targeted immunomodulator for asthma/COPD
    • Missing documentation of prior steroid trials or intolerance/contraindication when required